NUVALENT INC-A
NUVLNASDAQ🏆 #936 by market capEarnings Oct 28US Equity
$123.96▲ $0.00 (+0.00%)
Market closed · at closeTrack NUVL
Get earnings, price moves & breaking news on Telegram
24h▲ 0.0%
7d▲ 0.0%
14d▲ 0.0%
30d▲ 0.0%
ytd▲ 23.2%
1y▲ 43.1%
🏦Market Cap
$9.13B
Small Cap
📈Revenue Growth (YoY)
+0.0%
Slowing
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
64
Fair
NUVALENT INC-A
NUVLAnalyst Ratings
Price
$123.96
Total
19
Raised
0
Lowered
11
Avg PT
$127.32
H / L
$165 / $123
| Institution | Action | Rating | Date | Upside | |
|---|---|---|---|---|---|
Bernstein | Downgraded | Outperform → Market Perform | 2026-06-24 | $124.00 | +0.00% |
TD Cowen | Downgraded | Buy → Hold | 2026-06-10 | — | — |
Wedbush | Downgraded | Outperform → Neutral | 2026-06-10 | $124.00 | +0.00% |
UBS | Downgraded | Buy → Neutral | 2026-06-10 | $124.00 | +0.00% |
Truist Securities | Downgraded | Buy → Hold | 2026-06-10 | — | — |
Barclays | Downgraded | Overweight → Equal Weight | 2026-06-10 | $124.00 | +0.00% |
Guggenheim | Downgraded | Buy → Neutral | 2026-06-10 | $124.00 | +0.00% |
HC Wainwright & Co. | Downgraded | Buy → Neutral | 2026-06-09 | — | — |
LifeSci Capital | Downgraded | Outperform → Market Perform | 2026-06-09 | — | — |
Cantor Fitzgerald | Downgraded | Overweight → Neutral | 2026-06-09 | $135.00 | +8.90% |
Wells Fargo | Downgraded | Overweight → Equal Weight | 2026-06-09 | $124.00 | +0.00% |
JP Morgan | Reiterated | Overweight | 2025-12-19 | — | — |
Goldman Sachs | Reiterated | Buy | 2025-11-18 | $120.00 | −3.20% |
Baird | Reiterated | Outperform | 2025-11-18 | — | — |
Leerink Partners | Reiterated | Outperform | 2025-11-17 | $165.00 | +33.10% |
Stifel | Reiterated | Buy | 2025-11-17 | — | — |
Piper Sandler | Reiterated | Overweight | 2025-10-27 | $124.00 | +0.00% |
BMO Capital | Reiterated | Outperform | 2024-11-13 | $134.00 | +8.10% |
Cowen & Co. | Reiterated | Outperform | 2021-08-23 | — | — |
Institution
Bernstein
Downgraded · Outperform → Market Perform · 2026-06-24
$124.00
+0.00%
TD Cowen
Downgraded · Buy → Hold · 2026-06-10
—
—
Wedbush
Downgraded · Outperform → Neutral · 2026-06-10
$124.00
+0.00%
UBS
Downgraded · Buy → Neutral · 2026-06-10
$124.00
+0.00%
Truist Securities
Downgraded · Buy → Hold · 2026-06-10
—
—
Barclays
Downgraded · Overweight → Equal Weight · 2026-06-10
$124.00
+0.00%
Guggenheim
Downgraded · Buy → Neutral · 2026-06-10
$124.00
+0.00%
HC Wainwright & Co.
Downgraded · Buy → Neutral · 2026-06-09
—
—
LifeSci Capital
Downgraded · Outperform → Market Perform · 2026-06-09
—
—
Cantor Fitzgerald
Downgraded · Overweight → Neutral · 2026-06-09
$135.00
+8.90%
Wells Fargo
Downgraded · Overweight → Equal Weight · 2026-06-09
$124.00
+0.00%
JP Morgan
Reiterated · Overweight · 2025-12-19
—
—
Goldman Sachs
Reiterated · Buy · 2025-11-18
$120.00
−3.20%
Baird
Reiterated · Outperform · 2025-11-18
—
—
Leerink Partners
Reiterated · Outperform · 2025-11-17
$165.00
+33.10%
Stifel
Reiterated · Buy · 2025-11-17
—
—
Piper Sandler
Reiterated · Overweight · 2025-10-27
$124.00
+0.00%
BMO Capital
Reiterated · Outperform · 2024-11-13
$134.00
+8.10%
Cowen & Co.
Reiterated · Outperform · 2021-08-23
—
—
One row per institution · price target from the firm's latest published target